GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Ending Cash Position

Pharming Group (CHIX:PHARMA) Ending Cash Position : €55.6 Mil (As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Pharming Group Ending Cash Position?

Pharming Group's Ending Cash Position for the quarter that ended in Mar. 2025 was €55.6 Mil.

Pharming Group's quarterly Ending Cash Position declined from Sep. 2024 (€54.7 Mil) to Dec. 2024 (€52.5 Mil) but then increased from Dec. 2024 (€52.5 Mil) to Mar. 2025 (€55.6 Mil).

Pharming Group's annual Ending Cash Position declined from Dec. 2022 (€195.7 Mil) to Dec. 2023 (€56.6 Mil) and declined from Dec. 2023 (€56.6 Mil) to Dec. 2024 (€52.5 Mil).

Pharming Group Ending Cash Position Historical Data

The historical data trend for Pharming Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Ending Cash Position Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 168.64 169.85 195.73 56.62 52.47

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.74 43.80 54.66 52.47 55.59

Pharming Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pharming Group's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=58.963+-6.491
=52.5

Pharming Group's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=50.823+4.763
=55.6

Pharming Group Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Pharming Group's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Ending Cash Position
Comparable Companies
XAMS:VVY XAMS:GLPG VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX INSM HKSE:01801 SMMT RPRX XKRX:196170 INCY HKSE:02269 OCSE:GMAB
Traded in Other Exchanges
PHAR:USA PHGUF:USA PHARM:Netherlands 0QCO:UK PHGN:Germany
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Website
https://www.pharming.com
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines